

PHFPC Debriefing

Imelda Garcia, MPH

Associate Commissioner

Laboratory & Infectious Disease Services Division

October 12, 2022


DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. Information is subject to change.

October 12, 2022



COVID-19






Bivalent COVID-19 Booster Vaccines



Bivalent COVID-19 Booster Vaccines (Original + Omicron BA.4/BA.5)

- The bivalent vaccines contain the original strain of SARS-CoV-2 and the BA.4/BA.5 lineages of the Omicron variant, in equal parts
- Emergency use authorized as a single booster dose at least two months following primary or booster vaccination
- Bivalent Moderna COVID-19 booster vaccine authorized for individuals <u>></u>18 yrs
- Bivalent Pfizer COVID-19 booster vaccine authorized for individuals >12 yrs
- Monovalent mRNA COVID-19 vaccines are no longer authorized as booster doses for individuals >12 years



New Updated Pediatric Bivalent COVID-19 Booster Vaccines (Original + Omicron BA.4/BA.5)

- Authorization of bivalent COVID-19 booster vaccines for individuals 5 years and older is anticipated over the next couple of weeks.
- Pre-ordering is in progress.

Bivalent Pfizer COVID-19 Booster Vaccine*


- Single booster dose (10 mcg)
- 5-11 years
- Orange cap Bivalent
 - Different product than the monovalent orange cap
 - Dilution required
 - 10 doses/vial
 - Storage and handling identical to the current monovalent orange cap vaccine product
 - NDC: 59267-0565-02

Bivalent Moderna COVID-19 Booster Vaccine*

- Single booster dose
- 6 years and older
- Blue cap with grey border vial Bivalent
 - The same vaccine vial as for ≥18 yrs
 - Volume and dosage will differ by age
 - Adolescents 12-17 years same volume and dosage as for adults >18 yrs (0.5mL)
 - Children 6-11 years half the volume and doses as adults (0.25 mL)
 - Storage and handling identical to all current Moderna COVID-19 vaccine products




2022 Monkeypox Outbreak





Situational Update






Location	Cases			
United States Of America	26,577			
Brazil	8,207			
Spain	7,209			
France	4,043			
United Kingdom	3,654			
Germany	3,645			
Peru	2,587			
Colombia	2,453			
Location	Case Count			
California	5,135			
New York	3,984			
Florida	2,572			
■ Texas	2,410			
Georgia	1,839			
Illinois	1,332			
Pennsylvania	796			
New Jersey	723			
Maryland	682			
Washington	616			

Monkeypox Cases in Texas, as of 10/11/2022




Reported Monkeypox Cases in Texas by Public Health Region					
Public Health Region	Number of Cases				
PHR 1	9				
PHR 2/3	1,098				
PHR 4/5N	13				
PHR 6/5S	988				
PHR 7	262				
PHR 8	97				
PHR 9/10	6				
PHR 11	16				
Total	2,489				



Monkeypox Cases by Age/Gender, U.S.






Data as 10/5/2022. Available at: https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html. Accessed 10/11/2022.

Monkeypox Cases by Race/Ethnicity, U.S.







Data as 10/5/2022. Available at: https://www.cdc.gov/poxvirus/monkeypox/response/2022/demographics.html. Accessed 10/11/2022.

Monkeypox Case Report Trends: Texas






As of October 11, 2022, a total of 23,381 People Vaccinated (34,191 Doses) with JYNNEOS (ImmTrac2 data) in Texas



JYNNEOS Administration (ImmTrac2) by PHR					Cases	
PHR	One Dose		Total Doses Administered	%	Total Cases	%
1	110	42	152	0.4%	9	0.4%
2/3	6,779	2,972	9,757	28.5%	1,103	44.1%
4/5N	78	35	113	0.3%	13	0.5%
6/5S	9,162	5,005	14,179	41.5%	989	39.5%
7	4,172	1,486	5,662	16.6%	267	10.7%
8	1,245	456	1,701	5.0%	98	3.9%
9/10	338	64	402	1.2%	6	0.2%
11	836	472	1,309	3.8%	16	0.6%
Unknown	661	255	916	2.7%	0	0.0%
Total	23,381	10,787	34,191	100.0%	2,501	100.0%





Resources





- May 2022: What Clinicians Need to Know about Monkeypox in the United States and Other Countries:
 - https://emergency.cdc.gov/coca/calls/2022/callinfo_052422.asp
- June 2022: Monkeypox: Updates about Clinical Diagnosis and Treatment: https://emergency.cdc.gov/coca/calls/2022/callinfo_062922.asp
- July 2022: Monkeypox Outbreak: Updates on the Epidemiology, Testing, Treatment, and Vaccination: https://emergency.cdc.gov/coca/calls/2022/callinfo 072622.asp
- August 2022: CDC and FDA Update: Interim Clinical Considerations for Monkeypox Vaccination: https://emergency.cdc.gov/coca/calls/2022/callinfo 081122.asp
- October 2022: Situational Update for Clinicians about Severe Monkeypox Virus Infection:
 - https://emergency.cdc.gov/coca/calls/2022/callinfo_100622.asp

TPOXX Resources



<u>Treatment Information for Healthcare Professionals</u>

<u>Patient's Guide to Monkeypox Treatment with TPOXX</u>

<u>Study of Tecovirimat for Human Monkeypox Virus (STOMP)</u>

JYNNEOS Resources



- FDA EUA Fact Sheet for Providers: https://www.fda.gov/media/160774/download
- FDA EUA Fact Sheet for Patients and Caregivers: <u>https://www.fda.gov/media/160773/download</u>
 - Get the Fast Facts on the Intradermal JYNNEOS Monkeypox Vaccine, Simplified Chinese, Korean, Tagalog, Vietnamese, Spanish
- FDA: JYNNEOS Package Insert: https://www.fda.gov/media/131078/download
- Use of JYNNEOS (ACIP Recommendations)
- Vaccine Information Statement: Smallpox/Monkeypox Vaccine (JYNNEOS™): <u>https://www.cdc.gov/vaccines/hcp/vis/vis-statements/smallpox-monkeypox.pdf</u>
- JYNNEOS expiration Look-up: <u>Monkeypox (hhs.gov)</u>
- Vaccine Adverse Events Reporting System https://vaers.hhs.gov/
- Video: Administering JYNNEOS Intradermally
- https://www.cdc.gov/poxvirus/monkeypox/images/interim-considerations/administer-jynneos.zip

DSHS Resources



- EAIDU Monitoring: EAIDUMonitoring@dshs.texas.gov
- TPOXX requests: <u>dshsmpxconsult@dshs.texas.gov</u>
- Vaccine questions: DSHSMPXVax@dshs.texas.gov

DISCLAIMER

The information presented today is based current preliminary data and on CDC's recent guidance. Information is subject to change.

October 12, 2022